Abstract: The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the TNFRSF10B gene locus in a biological sample of said subject.

Abstract: The present invention relates to a method of detecting the presence of or predisposition to autism, or to an autism spectrum disorder, the method comprising detecting the presence of an alteration in the gene loci PITX1, ATP2B2, SLC25A12 and EN2 in a sample from said subject. More particularly, the presence of specific single nucleotide polymorphisms (SNPs) within these genes correlates to a substantially increased risk to develop autism.

Abstract: The present invention relates to a method for evaluating the level of risk for a subject to develop autism, or an autism spectrum disorder, which method comprises determining the number of risk alleles in autism-associated gene loci in a sample of a subject, wherein the more risk alleles are detected within said gene loci combined, the more increased is the risk of developing autism or an autism-spectrum disorder.

Abstract: The present invention relates to a diagnostic method of determining whether a subject, preferably an obese subject, is at risk of developing type 2 diabetes or diabetic complications, which method comprises detecting the presence of an alteration in the EEFSEC gene locus in a biological sample of said subject.

Abstract: The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the TNFRSF10C gene locus in a biological sample of said subject.

Abstract: The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the TNFRSF10A gene locus in a biological sample of said subject.

Abstract: The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PRKCB 1 gene on chromosome 16 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the PRKCBI gene and expression products, as well as to diagnostic tools and kits based on these mutations.

Abstract: The present invention relates to a diagnostic method of determining whether a subject, preferably an obese subject, is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the PEBP4 gene locus in a biological sample of said subject.

Abstract: The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the SHANK2 gene locus in a biological sample of said subject.

Abstract: The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the TNFRSF10D gene locus in a biological sample of said subject.

Abstract: The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PRKCB1 gene of chromosome 16 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the PRKCB1 gene and expression products, as well as to diagnostic tools and kits based on these mutations.

Abstract: The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PITX1 gene on chromosome 5 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the PITX1 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of pervasive developmental disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases.

Abstract: The present invention discloses the identification of a human obesity susceptibility gene; which can be used for the diagnosis, prevention and treatment of obesity and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PPYR1 gene on chromosome 10 and certain alleles thereof are related to susceptibility to obesity and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the PPYRI gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of coronary heart disease and metabolic disorders, including hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, coronary artery disease, diabetes and dyslipidemic hypertension.

Abstract: The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the SLC6A7 gene on chromosome 5 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the SLC6A7 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of Asperger syndrome, pervasive developmental disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases.

Abstract: The present invention relates to genetic mapping of complex quantitative and qualitative traits. This invention more particularly relates to compositions and methods to identify identical DNA fragments from two different DNA sources. The methods allow the amplification of the DNAs, their labelling, and the separation of perfectly matched DNAs from imperfectly matched DNAs or from DNAs formed through hybridization from the same source (e.g., homohybrids). The invention may be used to identify genes or gene mutations, which are relevant to pathological conditions or particular traits.

Abstract: The present invention discloses the identification of a human obesity susceptibility gene; which can be used for the diagnosis, prevention and treatment of obesity and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PPYR1 gene on chromosome 10 and certain alleles thereof are related to susceptibility to obesity and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the PPYR1 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of coronary heart disease and metabolic disorders, including hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, coronary artery disease, diabetes and dyslipidemic hypertension.

Abstract: The present invention relates to genetic mapping of complex quantitative and qualitative traits. This invention more particularly relates to compositions and methods to identify identical DNA fragments from two different DNA sources. The methods allow the amplification of the DNAs, their labelling, and the separation of perfectly matched DNAs from imperfectly matched DNAs or from DNAs formed through hybridization from the same source (e.g., homohybrids). The invention may be used to identify genes or gene mutations, which are relevant to pathological conditions or particular traits.

Abstract: The present invention relates to the field of genomics and genetic analysis, more particularly to genetic mapping of complex quantitative and qualitative traits. This invention more particularly relates to compositions and methods to identify haplotypes of associated allelic variants in nucleic acid fragments from different sources. The method allows the unambiguous identification of a trait-associated haplotype over large stretches of DNA up to several kilobases. The invention can be used to identify haplotypes related to various conditions or diseases, in particular to the ability of a subject to respond to therapeutic treatments.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one active compound having cytostatic activity, at least one biological electron acceptor and customary pharmaceutical additives, and to its use for the treatment of tumor diseases, in particular for the treatment of cancer.

Abstract: The present invention relates to a method for the identification of the presence of a genetic marker in a DNA sample, in particular by using a oligonucleotide array. In particular, the method according to the invention allows for the identification and/or localization of gene(s) associated with a distinguishable phenotype.